<DOC>
	<DOCNO>NCT01129960</DOCNO>
	<brief_summary>The primary objective study assess efficacy Eslicarbazepine acetate ( ESL ) therapy subject Diabetic Neuropathic Pain ( DNP ) 15 week treatment phase .</brief_summary>
	<brief_title>Eslicarbazepine Acetate Therapy Diabetic Neuropathic Pain</brief_title>
	<detailed_description>Diabetic neuropathic pain ( DNP ) one common complication diabetes mellitus . It currently affect 1 % population prevalence expect increase come year ( European Medicines Agency 2007 ) step increase diabetes mellitus prevalence , expect affect 220 million people 2010 The clinical development ESL treat neuropathic pain base chemical pharmacodynamic relationship sodium channel blocker , include carbamazepine , effective treat neuropathic pain condition . Preclinical data support theoretical background . This study examine efficacy , safety , tolerability pharmacokinetics Eslicarbazepine acetate treatment diabetic neuropathic pain .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Eslicarbazepine acetate</mesh_term>
	<criteria>Male female outpatient age 18 year old . Female subject nonchildbearing potential , defined surgical sterilization ( hysterectomy bilateral oophorectomy tubal ligation ) least 2 year postmenopausal ( spontaneous amenorrhea least 24 month Visit 1 ) , childbearing potential , subject agree use medically acceptable nonhormonal method contraception . Diagnosis Type 1 Type 2 diabetes mellitus . Pain due bilateral peripheral polyneuropathy cause Type 1 Type 2 diabetes mellitus . Have stable glycemic control , assess investigator , glycosylated hemoglobin proportion less equal 11 % randomization . A mean score 4.0 9.0 , inclusive , 24 hour average pain intensity assessment Visit 3 ( ie , 5 7 day , 6 8 day , 7 9 day , 7 10 day ) . Compliance patient diary completion . If use treat DNP , subject permitted take nonsteroidal anti inflammatory drug selective serotonin reuptake inhibitor keep stable dose 1 month prior Screening foreseen remain stable throughout study . Competent able freely give informed consent . Female subject childbearing potential , currently breastfeed , must negative serum pregnancy test Visit 1 . Historical exposure drug know cause neuropathy . Significant skin lesion ( active infection , ulcer , etc ) . Peripheral vascular disease history amputation , except amputation toe . Known intolerance ESL carboxamide derivative ( eg , carbamazepine oxcarbazepine ) frequent severe allergic reaction multiple medication . Subjects previously participate clinical study ESL . Major psychiatric disorder . Serious unstable disease could compromise participation cause hospitalization study . Second third degree atrioventricular blockade correct pacemaker clinically significant abnormality 12 lead electrocardiogram determine investigator . Subjects take follow drug class individual drug exclude : benzodiazepine ( except short half life sleep agent ) , skeletal muscle relaxant , orally administer steroid , capsaicin , mexiletine , centrally act analgesic ( dextromethorphan , tramadol ) , opiates , topical lidocaine , anticonvulsant , tricyclic antidepressant , serotonin norepinephrine reuptake inhibitor . These drug require minimum washout period least 5 time half life taper appropriately use product label instruction guide . Relevant clinical laboratory abnormality , investigator 's opinion , compromise subject 's safety . History drug abuse dependence ( drug category define DSM IV ) within past year , exclude nicotine caffeine . Subjects , previous 30 day , receive treatment drug receive regulatory approval indication time study entry . History recurrent epileptic seizure except febrile seizure . History severe gastroparesis gastric bypass surgery . Neurolytic treatment DNP . Injected anesthetic steroid use within 30 day Visit 1 . Malignancy within past 2 year . History chronic hepatitis B C within past 3 month human immunodeficiency virus infection .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Diabetic Neuropathic Pain</keyword>
</DOC>